Kiora says KIO-300 suppresses seizure activity in preclinical epilepsy model

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals, Inc. - Common Stock

KPRX

0.00
  • Kiora Pharmaceuticals disclosed preclinical epilepsy data for ion channel modulator KIO-300, presented June 18-19, 2026 at the Epilepsy Foundation Pipeline Conference.
  • The study showed KIO-300 reduced seizure-like activity in an ex vivo temporal lobe epilepsy model, supporting potential expansion beyond ophthalmology.
  • Effects persisted beyond dosing in the model, suggesting durability without broadly suppressing normal brain electrical signaling.
  • KIO-300 is the active ingredient in KIO-301, the company’s ongoing Phase 2 vision-restoration program in mutation-agnostic retinitis pigmentosa.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiora Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202606180700NEWSFILECNPR____20260618_301913_1) on June 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.